For: | Li N, Zhu QX, Li GZ, Wang T, Zhou H. Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1α and inhibiting the RhoA/ROCK pathway. World J Diabetes 2023; 14(12): 1862-1876 [PMID: 38222788 DOI: 10.4239/wjd.v14.i12.1862] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v14/i12/1862.htm |
Number | Citing Articles |
1 |
Ke-Xin Zhang, Cheng-Xia Kan, Fang Han, Jing-Wen Zhang, Xiao-Dong Sun. Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control. World Journal of Diabetes 2024; 15(2): 137-141 doi: 10.4239/wjd.v15.i2.137
Abstract(535) |
Core Tip(504) |
Full Article(HTML)(1949)
|
Full Article with Cover (PDF)-996K(109)
|
Full Article (Word)-280K(20)
|
Audio-7845K(4)
|
Peer-Review Report-194K(75)
|
Answering Reviewers-179K(58)
|
Full Article (PDF)-656K(211)
|
Full Article (XML)-80K(101)
|
Times Cited (1)
|
Total Visits (5168)
|
Open
|
2 |
Loredana N. Ionică, Adina V. Lința, Alina D. Bătrîn, Iasmina M. Hâncu, Bogdan M. Lolescu, Maria D. Dănilă, Lucian Petrescu, Ioana M. Mozoș, Adrian Sturza, Danina M. Muntean. The Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview. International Journal of Molecular Sciences 2024; 25(14): 7711 doi: 10.3390/ijms25147711
|
3 |
Sachin Dhiman, Sanchit Dhankhar, Anjali Garg, Manni Rohilla, Monika Saini, Thakur Gurjeet Singh, Samrat Chauhan, Samy Selim, Soad K. Al Jaouni, Sabina Yasmin, Naseem Begum, Aziza Alshahrani, Mohammad Yousuf Ansari. Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy. Heliyon 2024; 10(21): e39996 doi: 10.1016/j.heliyon.2024.e39996
|
4 |
Qiang Fan, Yabo Wang, Qi An, Yunfei Ling. Right ventricular dysfunction following surgical repair of tetralogy of Fallot: Molecular pathways and therapeutic prospects. Biomedicine & Pharmacotherapy 2025; 184: 117924 doi: 10.1016/j.biopha.2025.117924
|
5 |
Elina Khattab, Michaelia Kyriakou, Elena Leonidou, Stefanos Sokratous, Angeliki Mouzarou, Michael M. Myrianthefs, Nikolaos P. E. Kadoglou. Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives. Pharmaceuticals 2025; 18(1): 134 doi: 10.3390/ph18010134
|
6 |
Maja Muric, Ivan Srejovic, Jovana Novakovic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Marina Nikolic, Nevena Lazarevic, Marijana Andjic, Aleksandar Kocovic, Jovana Jakovljevic Uzelac, Sergey Bolevich, Vladimir Jakovljevic. The Combined Empagliflozin and Sacubitril/Valsartan Therapy Attenuates Isoproterenol-Induced Heart Failure in Rats: Functional, Molecular, and Structural Insights. Cardiovascular Drugs and Therapy 2025; doi: 10.1007/s10557-025-07675-4
|
7 |
Mina Y. George, Mohamed S. Dabour, Eman Rashad, Beshay N. Zordoky. Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy. Antioxidants 2024; 13(6): 671 doi: 10.3390/antiox13060671
|
8 |
Betul Rabia Erdogan, Ebru Arioglu-Inan. SGLT2 inhibitors: how do they affect the cardiac cells. Molecular and Cellular Biochemistry 2025; 480(3): 1359 doi: 10.1007/s11010-024-05084-z
|